The inhibitory effects of vanillin on the growth of melanoma by reducing nuclear factor-κB activation

被引:5
作者
Pourhadi, Marjan [1 ]
Ghasemi, Ahmad [1 ]
Abediny, Reza [1 ]
Haghjooy Javanmard, Shaghayegh [2 ]
Vaseghi, Golnaz [1 ,3 ]
机构
[1] Isfahan Univ Med Sci, Cardiovasc Res Inst, Appl Physiol Res Ctr, Esfahan, Iran
[2] Isfahan Univ Med Sci, Cardiovasc Res Inst, Appl Physiol Res Ctr, Sch Med,Dept Physiol, Esfahan, Iran
[3] Isfahan Univ Med Sci, Cardiovasc Res Inst, Isfahan Cardiovasc Res Ctr, Esfahan, Iran
关键词
melanoma; nuclear factor-kappa B; vanillin; CANCER-CELLS; METASTASIS; CARCINOMA; KINASE; TUMOR;
D O I
10.4103/abr.abr_280_21
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: Melanoma is skin cancer, and the treatments are not efficient enough. Therefore, finding new drugs seems to be an essential need. Vanillin, which is extracted from vanilla seed, has anti-cancer effects by reducing nuclear factor-kappa B (NF). We explored the anti-tumor effects of vanillin in the melanoma model and its possible mechanism. Materials and Methods: In the MTT assay, mice melanoma cells (B16F10) were treated with vanillin (1, 2, 3, 4, 5 mu g/mL) for 24 and 48 h. In an animal model, B16F10 was subcutaneously injected into C57BL/6 mice. After the development of tumors, the mice were treated with 50 and 100 mg/kg/day of vanillin for 10 days. The tumor size and expression level of NF-kappa B protein were measured. Results: In the MTT assay, vanillin in all concentrations significantly decreased B16F10 cell viability after 24 h incubation. The size of melanoma tumors was reduced in both doses 50 and 100 mg/kg/day in mice. NF-kappa B protein expression was decreased in the 100 mg/kg/day group in comparison with the control group. Conclusion: We found that vanillin by reducing NF-kappa B expression may have anti-tumor effects and reduced melanoma tumor size and cell viability.
引用
收藏
页数:6
相关论文
共 32 条
[1]   Nuclear factor-κB and inhibitor of κB kinase pathways in oncogenic initiation and progression [J].
Basseres, D. S. ;
Baldwin, A. S. .
ONCOGENE, 2006, 25 (51) :6817-6830
[2]   Overview of the Role of Vanillin on Redox Status and Cancer Development [J].
Bezerra, Daniel Pereira ;
Nascimento Soares, Anne Karine ;
de Sousa, Damiao Pergentino .
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2016, 2016
[3]   Activation of PPARγ Inhibits TLR4 Signal Transduction Pathway in Melanoma Cancer In Vitro [J].
Dana, Nasim ;
Vaseghi, Golnaz ;
Javanmard, Shaghayegh Haghjooy .
ADVANCED PHARMACEUTICAL BULLETIN, 2020, 10 (03) :458-463
[4]   The synergistic effect between vanillin and doxorubicin in ehrlich ascites carcinoma solid tumor and MCF-7 human breast cancer cell line [J].
Elsherbiny, Nehal M. ;
Younis, Nahla N. ;
Shaheen, Mohamed A. ;
Elseweidy, Mohamed M. .
PATHOLOGY RESEARCH AND PRACTICE, 2016, 212 (09) :767-777
[5]   Vanillin protects the blood-milk barrier and inhibits the inflammatory response in LPS-induced mastitis in mice [J].
Guo, Wenjin ;
Liu, Bingrun ;
Hu, Guiqiu ;
Kan, Xingchi ;
Li, Yanwei ;
Gong, Qian ;
Xu, Dianwen ;
Ma, He ;
Cao, Yu ;
Huang, Bingxu ;
Fu, Shoupeng ;
Liu, Juxiong .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 2019, 365 :9-18
[6]   Inhibiting NF-κB activation by small molecules as a therapeutic strategy [J].
Gupta, Subash C. ;
Sundaram, Chitra ;
Reuter, Simone ;
Aggarwal, Bharat B. .
BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS, 2010, 1799 (10-12) :775-787
[7]   Toxicology study of vanillin on rats via oral and intra-peritoneal administration [J].
Ho, KetLi ;
Yazan, Latifah Saiful ;
Ismail, Norsharina ;
Ismail, Maznah .
FOOD AND CHEMICAL TOXICOLOGY, 2011, 49 (01) :25-30
[8]   Apoptosis and cell cycle arrest of human colorectal cancer cell line HT-29 induced by vanillin [J].
Ho, KetLi ;
Yazan, Latifah Saiful ;
Ismail, Norsharina ;
Ismail, Maznah .
CANCER EPIDEMIOLOGY, 2009, 33 (02) :155-160
[9]  
Huang S, 2000, CLIN CANCER RES, V6, P2573
[10]   Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18F-FDG-microPET or external caliper [J].
Jensen M.M. ;
Jørgensen J.T. ;
Binderup T. ;
Kjær A. .
BMC Medical Imaging, 8 (1)